Job Code 322DR
Fate Therapeutics is currently seeking a talented and highly motivated scientist with a strong background in the latest functional genomics approaches to join a multidisciplinary team dedicated to the discovery of novel induced pluripotent stem cell (iPSC) derived cellular therapeutics. The candidate must have extensive hands-on experience in current molecular biology techniques including donor plasmid template design and construction, DNA assembly methods, conventional and real-time PCR. The successful candidate must also be highly skilled in the latest genomic editing techniques (CRISPR/Cas9, Cpf1, etc.) used for both knockout and knock-in of specific gene sequences. The candidate will also be responsible for identifying and developing novel cell barcoding techniques compatible with next generation sequencing (NGS) detection. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time, bench-level position reporting to the Associate Director, Genomics and is located at the Company’s corporate headquarters in San Diego, California.
Download a PDF of the job description for more details:
For consideration send cover letter and curriculum vitae to: firstname.lastname@example.org and reference job 322DR.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.